1. Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial
infarction (STEMI) subgroups of major clinical trials on novel oral antithrombotic agents
Figure 3 | Ischaemic outcomes in the ST-segment elevation myocardial infarction (STEMI) subgroups of major clinical trials on novel oral antithrombotic agents. Risk reduction of novel antithrombotic agents versus dual antiplatelet therapy with aspirin and clopidogrel in post-hoc analyses on the STEMI subgroups of clinical trials performed in patients with acute coronary syndromes. Major adverse cardiovascular events are the primary end point of each trial. *Results are reported for the comparison between rivaroxaban 2.5 mg versus placebo.
Franchi, F. et al. (2017) Antithrombotic therapy for patients with STEMI undergoing primary PCI
Nat. Rev. Cardiol. doi: /nrcardio